{
    "nct_id": "NCT05806567",
    "official_title": "A Three-part, Sequential, Non-randomized, Open-label Study Designed to Evaluate the Effect of Oral Belumosudil on UGT1A1, P-gp, BCRP and OATP1B1 Inhibition in the Fed State in Healthy Male Subjects",
    "inclusion_criteria": "* Healthy male participants aged 18 to 55 years old\n* Must agree to use an adequate method of contraception\n* Must be able to understand and provide a written informed consent\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "Participants are excluded from the study if any of the following criteria apply:\n\n* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.\n* Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.\n* Significant serious skin disease, including rash, food allergy, eczema, psoriasis, or urticaria.\n* Failure to satisfy the investigator of fitness to participate for any other reason.\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.",
    "miscellaneous_criteria": ""
}